“Whatwe’reafterhereissomethingcalledactive allyship,”saidDr. DwinitaMosby Tyler, CEO and founder of The Equity Project in her keynote address at ACR Convergence 2024.“It’swhereyouwitnesssomethingthatmightbeaninjusticeoryoumightseeadisparity,andyoudon’tjusttalkaboutit,youresearchit; youdosomethingaboutit.”
WASHINGTON, D.C.—Retroperitoneal fibrosis (RPF) is often a challenging diagnosis to make, given a lack of serologic biomarkers and often difficulty in accessing tissue for biopsy, especially in cases confined to the retroperitoneum. The topic of retroperitoneal fibrosis was discussed during the CARE to Test Your Knowledge: Retroperitoneal Fibrosis session at ACR Convergence 2024. John Stone,…
With the U.S. Food & Drug Administration’s approval in 2014 of asfotase alfa for replacement of tissue-non-specific alkaline phosphatase (TNSALP or TNAP) in juvenile-onset hypophosphatasia (HPP), rheumatologists have a responsibility to recognize the more subtle manifestations of this condition in adults to avoid missed treatment opportunities for fractures, dental loss and musculoskeletal pain. Hypophosphatasia is…
For the 2024 Image Competition, the ACR sought images representing a diverse range of patients with educational or remarkable manifestations of pediatric rheumatic diseases, including autoimmune, inflammatory, infectious and malignant drivers of pediatric rheumatic disease. Here, we showcase the images selected as Best Overall. Cavitary Lung Nodules with Sinus & Skin Disease in Pediatric ANCA-Associated…
The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities that will affect both the practice of rheumatology and patient care in the year ahead. The Coalition, composed of leading rheumatology professional societies and patient advocacy groups, gathered to examine…
Changes to Medicare benefits in 2025 include an annual $2,000 cap on out-of-pocket costs for covered Part D drugs and a new, voluntary Medicare Prescription Payment Plan intended to help beneficiaries manage drug costs.
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.